Cellino is a closed loop cell therapy manufacturing company that aims to make stem cell-based regenerative therapies available to all eligible patients and researchers using cells in clinical research.
Gilead has announced they are pulling cancer drug Zydelig (idelalisib) off the market for certain types of cancer after failing to complete follow-up clinical trials to confirm efficacy and safety.
After receiving daily doses of the therapeutic, 71% of the children could tolerate the equivalent of 16 peanuts and six months later, 21% of them still could.
ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.
The companies announced that Dupixent was the first biologic to significantly reduce itch and skin lesions in patients with Prurigo Nodularis in the Phase III trial.
